{
    "2018-01-17": [
        [
            {
                "time": "2018-01-17",
                "original_text": "复星医药：两子公司获批准白血病治疗药物临床试验",
                "features": {
                    "keywords": [
                        "复星医药",
                        "白血病",
                        "治疗药物",
                        "临床试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2018-01-17",
                "original_text": "复星医药：创新药全面布局 买入评级",
                "features": {
                    "keywords": [
                        "复星医药",
                        "创新药",
                        "买入评级"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-17",
                "original_text": "【重磅！】上海钢联深度：利润拐点在即，进入长期成长轨道（Fintech系列深度之七）",
                "features": {
                    "keywords": [
                        "上海钢联",
                        "利润拐点",
                        "长期成长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "钢铁",
                        "金融科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-17",
                "original_text": "【医药-复星医药(600196)】江琦、张天翼：从单抗到小分子，创新药全面布局 - 20180117",
                "features": {
                    "keywords": [
                        "复星医药",
                        "单抗",
                        "小分子",
                        "创新药"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-14",
                "original_text": "【山证医药】医药生物行业周报（20180108-20180114）：2017年度业绩预告陆续发布",
                "features": {
                    "keywords": [
                        "医药生物",
                        "行业周报",
                        "业绩预告"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-17",
                "original_text": "银河生物控股公司马力喏首席科学顾问陈思毅：两三年后CAR-T疗法赛道将现“裸泳者”",
                "features": {
                    "keywords": [
                        "银河生物",
                        "CAR-T疗法",
                        "裸泳者"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}